`Interesting' Juxtaposition

In his article, Hubel pointed out the ties between the terrorist Animal Liberation Front and the above-ground People for the Ethical Treatment of Animals. A January 1992 publication of the Office of Technology Assessment (Technology Against Terrorism: Structuring Security) links these groups with Barnard's own organization, the Physicians Committee for Responsible Medicine, whose views, the OTA report notes, appear "to have little s

Written bySharon Russell
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In his article, Hubel pointed out the ties between the terrorist Animal Liberation Front and the above-ground People for the Ethical Treatment of Animals. A January 1992 publication of the Office of Technology Assessment (Technology Against Terrorism: Structuring Security) links these groups with Barnard's own organization, the Physicians Committee for Responsible Medicine, whose views, the OTA report notes, appear "to have little support within the medical community" (page 27). Some of Barnard's comments clearly illustrate why this should be the case.

For example, Barnard makes the unsubstantiated claim that more than half the drugs marketed from 1976 through 1985 "were so much more toxic than premarket animal and limited human trials had indicated that they had to be relabeled or withdrawn." I am not certain how serious a problem "relabeling" is, but according to the Office of Planning and Evaluation (OPE) of the United States Food and Drug Administration, only ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies